Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers

References

• Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Brilique, summary of product characteristics, 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001241/WC500100494.pdf [Last accessed 9 January 2012]
   Google Scholar
• Brilinta™, US full prescribing information, July 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022433s000lbl.pdf [Last accessed 9 January 2012]
   Google Scholar
• Hamm CW, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32:2999-3054
   PubMed Web of Science ®Google Scholar
• Steg G, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619
   PubMed Web of Science ®Google Scholar
• Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management. Mayo Clin Proc 2009;84:917-38
   PubMed Web of Science ®Google Scholar
• Taneva E, Bogdanova V, Shtereva N. Acute coronary syndrome, comorbidity, and mortality in geriatric patients. Ann N Y Acad Sci 2004;1019:106-10
   Google Scholar
• Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician 2000;61:1745-54
   PubMed Web of Science ®Google Scholar
• Drug interaction studies – study design, data analysis, and implications for dosing and labelling. Food and Drug Administration, February 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf [Last accessed 1 March 2013]
   Google Scholar
• Zanger UM, Turpeinen M, Klein K, et al. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug transformation. Anal Bioanal Chem 2008;392:1093-108
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687-710
   PubMed Web of Science ®Google Scholar
• Teng R, Oliver S, Hayes M, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010;38:1514-21
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability, and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010;66:487-96
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics and safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010;70:65-77
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-6
   PubMed Web of Science ®Google Scholar
• Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug–drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos 2011;39:703-10
   PubMed Web of Science ®Google Scholar
• Diltiazem, summary of product characteristics, February 2011. Available at: http://www.medicines.org.uk/emc/medicine/23945/SPC/diltiazem%20hydrochloride%20tablets%2060mg/ [Last accessed 9 January 2012]
   Google Scholar
• Zhao P, Lee CA, Kunze KL. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab Dispos 2007;35:704-12
   PubMed Web of Science ®Google Scholar
• Zhang X, Quinney SK, Gorski JC, et al. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos 2009;37:1587-97
   PubMed Web of Science ®Google Scholar
• Playford EG, Webster AC, Sorrell TC, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006;57:628-38
   PubMed Web of Science ®Google Scholar
• Ketoconazole, summary of product characteristics, July 2010. Available at: http://www.medicines.org.uk/emc/medicine/912 [Last accessed 9 January 2012]
   Google Scholar
• Greenblatt DJ, Zhao Y, Venkatakrishnan K, et al. Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol 2011;63:214-21
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Huang H-LA, Slade A, et al. The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. Br J Clin Pharmacol 2009;68:381-5
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect, in healthy subjects. Can J Clin Pharmacol 2008;15:e426
   Google Scholar
• Teng R, Butler K. Safety, tolerability, pharmacokinetics and pharmacodynamics of high single-ascending doses of ticagrelor in healthy volunteers. 2012; Submitted
   Google Scholar
• Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B 2010;878:2299-306
   PubMed Web of Science ®Google Scholar
• Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-22
   PubMed Web of Science ®Google Scholar
• van Giezen JJJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009;7:1556-65
   PubMed Web of Science ®Google Scholar
• Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZd1640, the first reversible, oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2007;50:1844-51
   PubMedGoogle Scholar
• James S, Åkerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605
   PubMed Web of Science ®Google Scholar
• Sutton D, Butler AM, Nadin L, et al. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 1997;282:294-300
   PubMed Web of Science ®Google Scholar
• Fitch WL, Tran T, Young M, et al. Revisiting the metabolism of ketoconazole using accurate mass. Drug Metab Lett 2009;3:191-8
   PubMedGoogle Scholar
• Teng R, Mitchell PD, Butler K. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol 2013;69:477-87
   PubMed Web of Science ®Google Scholar
• Diczfalusy U, Miura J, Roh HK, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 2008;18:201-8
   PubMed Web of Science ®Google Scholar